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Case presentation
A 38-year-old black male was referred for the evaluation of recent-
onset hypertension. He had formerly been a professional athlete, who
had been normotensive 6 years earlier. Since retiring from athletics, he
had gained 60 lbs and had performed little exercise. He had smoked one
to one and one-half packs of cigarettes daily for 10 years, and he drank
3 to 5 beers per day. He had a strong family history of cardiovascular
disease: his mother died at age 42 of hypertension and a cerebrovascu-
lar accident, and his father died at age 55 with hypertension and a
myocardial infarction.
Physical examination revealed a healthy black male, whose weight
was estimated to be 25% above the upper limits of his ideal body
weight. The blood pressure was 150—158/98—104 mm Hg in both arms.
The pulse rate was 60—66 beats/mm on multiple determinations over one
month. Funduscopic examination revealed mild arteriolar narrowing
and arteriovenous crossing changes. jugular venous pressure was
estimated to be 4—6 cm H20. No carotid bruits were heard. Lung
examination was normal. The PMI was normal, as were 51 and S2. An
S4 was present. No murmurs, clicks, or rubs were present. Abdominal
examination disclosed no visceromegaly, bruits, or masses. Rectal
examination was unremarkable. The pulses in the extremities were
normal, and there was no pulse lag between the arms and legs. No
edema was present. Neurologic examination was normal.
Laboratory studies revealed: sodium, 142 mEq/liter; potassium, 3.3
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mEq/liter; bicarbonate, 25 mEq/liter; chloride, 104 mEq/liter; blood
urea nitrogen, 15 mg/dl; creatinine, 1.1 mg/dI; and cholesterol, 228
mg/dl. A complete blood count, as well as tests for glucose, uric acid,
thyroid function, calcium, phosphorus, and albumin all were normal, as
were urinalysis and chest i-adiographs. An electrocardiogram revealed
regular rate and rhythm with an axis of 0°, and normal PR, QRS, and QT
intervals. There were no abnormalities of T waves, ST segments, or
voltage. Creatinine clearance was 115 ml/min; 24-hour excretions were:
sodium, 172 mEq, and potassium, 33 mEq.
On his usual sodium and potassium intake, the 4-hour upright plasma
renin activity (PRA) was 0.3 ng AL/mI/hr and the plasma aldosterone
(PA) was 18.2 ng/dl. Following infusion of 2 liters of 0.9% sodium
chloride, the PRA was .01 ng A1/ml/hr, and the PA was 4.1 ng/dl.
A diagnosis of low-renin essential hypertension was made. The
patient elected to pursue a non-drug treatment program for his hyper-
tension. He began a sodium chloride-, calorie-, and fat-restricted diet
and was urged to seek counseling for his cigarette and alcohol use. Over
the next 6 months, the patient stopped smoking and gave up alcohol but
was not able to lose weight or maintain a sodium chloride-restricted
diet. The blood pressure was 146/98 rum Hg; pulse was 72 beats/mm.
The serum potassium was 3.2 mEq/liter, and a 24-hr urine collection
contained 38 mEq of potassium and 125 mEq of sodium. The patient
was asked to seek dietary counseling to reduce his sodium chloride
intake.
Over the next 3 months, he was able to decrease his sodium chloride
intake. His blood pressure remained at 148/98 mm Hg, however. The
serum potassium was 3.3 mEq/liter; the 24-hr urinary potassium was 29
mEq, and the sodium 68 mEq. A timed-release potassium chloride
preparation (20 mEq three trmes daily) was recommended. After 3
months, his blood pressure fell to 135/88 mm Hg, the serum potassium
was 3.9 mEq/liter, and the 24-hr urinary potassium was 82 mEq. Over
the ensuing 6 months, his blood pressure remained at 130—138/82—88
mm Hg and the serum potassium was 3.8-4.2 mEq/liter. The patient
was told to discontinue the potassium supplement and to substitute
fruits and vegetables high in potassium. Over the ensuing 6 months, his
blood pressure was 145—152/93—99 mm Hg; serum potassium, 3.1—3.5
mEq/liter; and 24-hr urinary potassium, 35—45 mEq. The potassium
supplement was restarted, and his blood pressure has remained at
128—138/82—90 mm Hg.
Discussion
DR. STUART L. LINAS (Chief, Nephrology Division, Denver
General Hospital, and Professor of Medicine, University of
Colorado School of Medicine, Denver, Colorado): Although
nonpharmacologic maneuvers have long been recognized as
important in the management of high blood pressure, these
interventions have been evaluated critically only in the last
decade. In this patient, for example, it would be entirely
appropriate to recommend weight loss, smoking cessation, and
reduction of alcohol intake in an initial attempt at reducing
blood pressure and its damaging effect on blood vessels. Obe-
sity clearly is associated with hypertension as well as with
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increased cardiovascular morbidity and mortality [1, 21. Fur-
thermore, the distribution of body fat appears to be an indepen-
dent predictor of risk: abdominal or truncal fat deposition is
associated with greater cardiovascular risk than is overall
obesity [3, 4]. Although smoking is not associated with changes
in blood pressure per se [51, it increases cardiovascular mor-
bidity and mortality in subjects with hypertension. In the
Nurses Health study of 119,404 female nurses, the risk of
coronary disease was not only increased in smokers compared
with nonsmokers, but it was dramatically increased in hyper-
tensive smokers compared with normotensive nonsmokers [61.
A direct relationship also appears to exist between alcohol
intake and blood pressure. Consumption of more than 2 drinks
per day increases blood pressure in some groups. This relation-
ship appears to be stronger in whites, men, and those over age
45 than in blacks, women, and those under 45 [7—9]. Alcohol
also can offset the effects of antihypertensive drug therapy. This
"drug" is a frequent, and often overlooked, cause of resistant
hypertension [10].
The effect of changing the dietary consumption of micronu-
trients such as sodium, potassium, calcium, magnesium, chlo-
ride, and phosphorus on blood pressure is disputable. Hyper-
tension in this patient appeared to respond to the administration
of potassium supplementation, so I will take this opportunity to
summarize the data on the role of potassiuth in the pathogenesis
and treatment of hypertension and stroke. To accomplish this
goal, I will summarize the epidemiologic as well as the inter-
ventional data with regard to potassium.
Epidemiology
In 1928 Addison concluded that "One has forced on one the
concept that the prevalence of arterial hypertension on this
continent is in large part due to a potash poor diet, and an
excessive use of salt (sodium chloride) as a condiment, and as
a preservative of meat" [11]. In 1931 Priddle stated that ". . . it
will be necessary for all cases with well established hyperten-
sion to continue indefinitely their diet regulations (low sodium
diet), and in many, the high intake of potassium as well" [121.
Over the next half century, numerous epidemiologic reports on
the relationship between potassium and hypertension appeared.
Walker et al studied the relationship between urinary potas-
sium excretion and blood pressure in 574 normotensive and
hypertensive subjects [13]. Patients with diastolic blood pres-
sures greater than 90 mm Hg had lower urinary potassium
concentrations and lower potassium-to-creatinine ratios than
did subjects whose diastolic blood pressures were 90 mm Hg or
below. Because sodium and creatinine cOncentrations were
comparable in both groups, it seemed unlikely that differences
in sodium or water intake accounted for the differences in
urinary potassium. These investigators suggested the possibility
of a pathogenetic role of potassium on high blood pressure.
Watson et a! looked at blood pressure and urinary electrolyte
excretion in adolescent and young adult females in Hinds
County, Mississippi [14]. They studied black women and white
women and found a positive correlation between the sodium-
potassium ratio and blood pressure, and an inverse relationship
between potassium excretion (or potassium excretion/weight)
and blood pressure. Lever et al determined the relationship
between blood pressure and plasma, exchangeable (isotope
dilution), and total-body potassium (measured by external
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Fig. 1. Relation of plasma potassium concentration and diastolic
blood pressure in patients with essential hypertension (r = —0.51, P <
0.001). (From Ref. 16.)
counting of potassium40) in patients with essential hypertension
who had either never been on drug therapy or in whom drugs
had been withdrawn for a minimum of 4 weeks [15, 161. All
three indices of potassium metabolism correlated significantly
but negatively with systolic and diastolic pressures (Fig. 1), and
the relationship between potassium and blood pressure ap-
peared stronger in younger (< 36 years) than in older (> 49
years) patients.
In Japan, Kihara et a! studied the majority (62%) of 1818
inhabitants of a rural village [171. The subjects were males and
females over 30 years of age who had a traditional Japanese
lifestyle and who consumed large amounts of sodium. Single
spot urine samples obtained while subjects were fasting were
used to estimate dietary intake. The sodium-to-potassium ratio
was positively associated with blood pressure (especially sys-
tolic) in both sexes; the potassium-to-creatinine ratio was
negatively associated with blood pressure in men but not in
women.
Khaw and Barrett-Connor performed a population-based
study of 685 men and women in a predominantly white com-
munity in southern California [18]. The potassium intake was
estimated by the subject's recall of the diet over the previous 24
hours. In men, age-adjusted systolic blood pressure and dias-
tolic blood pressure correlated negatively both with potassium
consumption from fruit and vegetables as well as with total
potassium intake. In women, only age-adjusted systolic blood
pressure correlated with potassium intake. For both sexes,
systolic blood pressure decreased by 1.7 to 1.8 mm Hg for every
10 mmol increase in potassium intake from fruit and vegetables,
and by 1.0 to 1.2mm Hg for every 10 mmol increase in the total
potassium intake.
These investigators have extended their observations and
reported on additional subjects within this population including
584 men and 718 women [191. In these studies, age-adjusted
systolic and diastolic blood pressure correlated negatively with
potassium intake both in men and women. In addition, in both
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sexes, age-adjusted systolic and diastolic blood pressure corre-
lated positively with the urinary sodium-to-potassium ratio
(Fig. 2). The correlations were stronger for the sodium-to-
potassium ratio than were those for potassium alone. In men,
they found marked differences in the relationship between
systolic and diastolic blood pressure and the urinary sodium-
to-potassium ratio in younger versus older men. For men under
50 years, the regression slope was not significant; by contrast
(and in contradistinction to other studies [15, 16]), the regres-
sion slope was significant for men over age 50. No consistent
age trends were found in women.
Some evidence suggests that blacks excrete (and presumably
consume) less potassium than do whites. In 1961 a random
sample of the black and white populations of Evans County,
Georgia, revealed that blacks had a greater prevalence of
hypertension than did whites [20]. Whereas blacks and whites
consumed comparable quantities of sodium, potassium intake
was consistently lower in blacks. For example, as suggested by
24-hour urine data, black males consumed approximately 60%
of the potassium consumed by white males, and black females
consumed 75% of the potassium consumed by white females.
Watson et al found similar differences in urinary potassium
excretion between black and white females in Hinds County,
Mississippi [14]. Moreover the urinary sodium-to-potassium
ratio was 4.1 in the black females and 2.9 in the whites. In
another study, Dai et al evaluated the urinary electrolyte
excretion in blacks and whites in 3 cities in the United States:
Pueblo, Colorado; Hagerstown, Maryland; and Savannah,
Georgia [211. Blacks had higher blood pressures as well as
higher urinary sodium and lower urinary potassium excretion
than did whites.
In addition to the apparent inverse relationship between
dietary potassium intake and blood pressure, recent studies
have suggested an inverse relationship between dietary potas-
sium intake and stroke-associated mortality. Khaw and Barrett-
Connor examined the relationship between these factors in 859
men and women in an upper-middle-class white community in
Fig. 2. Age-adjusted mean sodium (mmol)-to-
potassium (mmol) ratio by systolic and diastolic
blood pressure category in Rancho Bernardo men
and women 30—79 years old. (From Ref. 19.)
southern California [221. The population was followed for 12
years, during which 24 stroke-associated deaths occurred. The
relative risk of stroke was 2.6 in men and 4.8 in women in
individuals consuming the lowest amounts of potassium (< 59
mmol in men and <49 mmol in women) compared with those
consuming more. This effect was independent of other known
cardiovascular risk factors including age, high cholesterol,
obesity, high blood sugar, and cigarette use. Moreover, the
negative effects of potassium were independent of blood pres-
sure. Multivariate analysis suggested that a 10 mmol increase in
dietary potassium was associated with a 40% reduction in the
risk of stroke-associated mortality.
In summary, epidemiologic studies have yielded the follow-
ing conclusions: (1) An inverse relationship exists between
potassium intake and blood pressure. (2) A positive relationship
exists between the urinary sodium-to-potassium ratio and blood
pressure; this relationship might be stronger in men (especially
older men) and in blacks. (3) An inverse relationship is likely
between potassium intake and stroke-associated mortality. Al-
though the relationship between potassium and blood pressure
appears to be based on solid epidemiologic data, there is a high
degree of correlation among a number of dietary factors,
including potassium, calcium, and protein [23]. Thus the inde-
pendent role of any specific nutrient on blood pressure cannot
be conclusively ascertained from epidemiologic studies.
Intervention studies
Human investigations. Over the last decade, several studies
have focused on the effect of increased potassium intake on
blood pressure. For the most part, potassium has been provided
in pharmacologic preparations rather than in the diet. In nor-
motensive subjects, increases in potassium intake produce little
or no effect on blood pressure. Burstyn and colleagues deter-
mined the effect of a two-stage increase in potassium intake on
blood pressure in normotensive subjects [24]. Subjects were
studied during a high-salt intake and after an increase in
potassium chloride intake of 40% (8 days) and then a further
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increase of 55% (above the 40% increase, 14 days). Increases in
potassium intake did not change systolic or diastolic pressure.
Barden and coworkers performed a two-period crossover study
in 44 normotensive women who had low urinary potassium
excretions [251. Patients were randomized and given either 80
mmol/day of potassium chloride or matching placebo for 4
weeks; the regimen was reversed for an additional 4 weeks. No
consistent changes in blood pressure were noted during potas-
sium supplementation. Miller et al investigated the effect on
blood pressure of a small potassium supplementation in 38
healthy white families [26, 27]. Normotensive, school-aged,
identical twins and their parents were studied under basal
conditions. In each family, both parents and one twin were
studied after receiving a non-chloride, liquid potassium supple-
ment for 4 weeks while the second twin received placebo.
Although urinary potassium excretion increased significantly
both in adults and children consuming supplemental potassium,
neither systolic nor diastolic blood pressure changed. In con-
trast, Khaw and Thom found small decreases in diastolic
pressure (2.4 mm Hg) but no change in systolic pressure in 20
normotensive males studied in a randomized, double-blind,
crossover design with oral potassium chloride (64 mmol/day for
2 weeks) versus placebo [28].
Potassium supplementation in patients with essential hyper-
tension has a small to moderate antihypertensive effect, but this
effect is not seen in every patient. MacGregor et al studied 23
patients (12 men, 11 women, 18 blacks, 5 whites) with mild to
moderate essential hypertension entered into an 8-week double-
blind, randomized crossover study of slow-release potassium
(60 mmollday) versus placebo [29]. Compared with placebo,
after 4 weeks of potassium, supine systolic blood pressure fell
from 155 3 mm Hg to 148 3 mm Hg and diastolic blood
pressure from 99 2 mm Hg to 95 2 mm Hg. The absolute
and percentage of decreases in blood pressure during potassium
therapy related directly to the height of blood pressure during
placebo therapy. However, 5 patients had decreases in mean
arterial pressure of at least 8 mm Hg; 2 had decreases in mean
arterial pressure of 6 to 8 mm Hg, 15 patients had decreases or
increases between +5 and —5 mm Hg, and in one patient the
increase was greater than 6 mm Hg. Matlou and colleagues
found that the administration of potassium chloride (65 mmol/
day) reduced blood pressure from 153/104 mm Hg to 146/101
mm Hg in 32 hypertensive black women during a 6-week
randomized, placebo-controlled, crossover trial [30]. The anti-
hypertensive effects of potassium chloride were observed only
after 6 weeks of therapy. No statistically significant decreases
in blood pressure were apparent after 2 or 4 weeks of therapy
with potassium chloride. Considerable individual variability
was noted: after 4 to 6 weeks, systolic blood pressure decreased
in 23 patients and increased in 9; diastolic blood pressure
decreased in 18 patients, increased in 13, and remained un-
changed in one.
Svetky et al performed a double-blind trial in 2 groups of
patients with mild hypertension [31]. Microencapsulated potas-
sium (120 mmol/day for 8 weeks) was compared with placebo.
Although systolic blood pressure fell in the potassium-treated
group by 6.4 14 mm Hg (SD) and diastolic by 4,1 8 mm Hg
compared with 0.1 13 mm Hg and 1.6 7 mm Hg in
placebo-treated patients, baseline blood pressure was some-
what higher in potassium-treated patients than in those treated
with placebo. Because the antihypertensive effects of potas-
sium might depend on basal blood pressures, these studies
might have overestimated the antihypertensive effects of potas-
sium. In support of this hypothesis, Cushman and Langford
presented preliminary data on the effect of 80 mmollday of
potassium chloride for 10 weeks versus placebo in mildly
hypertensive black or white men [32]. Blood pressure did not
change after potassium administration either in blacks or
whites.
All the studies I just reviewed suffer by being quite short in
duration. In contrast, Siani and coworkers [33] and Obel [34]
reported on longer trials of potassium supplementation. Siani et
al performed a double-blind, placebo-controlled trial of oral
potassium supplementation (48 mmol/day) (Fig. 3). An antihy-
pertensive effect of potassium was first observed after 3 weeks;
it reached its peak at 15 weeks when the study was stopped.
Both systolic and diastolic blood pressure decreased (14 mm Hg
and 7 mm Hg, respectively). Supine systolic blood pressure fell
by at least 10 mm Hg, and diastolic blood pressure by at least 7
mm Hg, in 11 of 18 patients receiving potassium. Obel reported
profound antihypertensive effects of potassium supplementa-
tion in a double-blind trial comparing potassium (64 mmollday)
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Fig. 3. Average supine and standing blood pressures of 18 hyperten-
sive patients receiving oral potassium supplement of 48 mmol/day (•)
and of 19 patients receiving placebo (0) over 15 weeks (*P < 05,
< .01, < .001). (From Ref. 33.)
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Table I. Possible mechanisms of the antihypertensive effect of
potassium
1. Natriuresis/diuresis
2. Decreases in pressor hormone levels
Renin-angiotensin-aldosterone
Norepinephrine
3. Increases in vasodilator hormones
4. Effect on blood vessel wall
Decreased pressor hormone responsiveness
Direct vasodilation
5. Increased baroreceptor sensitivity
with placebo in 48 black patients with mild essential hyperten-
sion in Nairobi, Kenya [341. After 16 weeks of potassium
administration, supine systolic blood pressure fell by 42 mm Hg
and diastolic blood pressure by 17 mm Hg (175/100 to 133/83
mm Hg) compared with no changes in systolic or diastolic blood
pressure in placebo-treated patients (173/100 to 172/100 mm
Hg). Although there is no readily apparent explanation for the
discrepancy between the findings of Obel and others, it is
possible that subjects in the Kenyan study reduced sodium
intake as well.
In short, it appears that potassium supplementation has an
antihypertensive effect, albeit one that varies considerably from
patient to patient. Just as with other pharmacologic and non-
pharmacologic maneuvers, potassium's effect can be demon-
strated in hypertensives but not in normotensives. The most
dramatic effects of potassium supplementation have been ob-
served in longer clinical trials. Although there is some sense
that the antihypertensive effect of potassium administration is
easier to demonstrate in blacks than in whites, this supposition
has not been carefully substantiated.
In addition to the use of potassium as a primary treatment of
hypertension, potassium supplementation has been used as an
adjunct to diuretics in the treatment of hypertension. Kaplan et
al questioned whether decreases in potassium that occur in
patients treated with diuretics might offset the antihypertensive
properties of diuretics [351. Twenty hypertensives with diuretic-
induced hypokalemia underwent a 16-week, randomized, dou-
ble-blind crossover trial comparing potassium-chloride (60
mmol/day slow-release compound) with placebo. Sixteen pa-
tients completed the trial. Diuretics were continued throughout
both arms of the trial. Thirteen patients were black and 3 were
white; 6 were men and 10 were women. Compared with the
placebo period, mean supine blood pressure decreased from 109
2 to 104 2 mm Hg (P =
.004) during potassium chloride
therapy. In 9 of 16 patients, blood pressure decreased by 4 mm
Hg or more during potassium chloride administration. In the
other 7 patients, mean blood pressure fell by less than 4 mm Hg
(N = 5), or it increased (N = 2). Four other patients had to be
dropped from the study because potassium measurements in
serum and urine suggested that they had not taken adequate
potassium supplements. Although the results of this study
indicated that potassium chloride might further reduce blood
pressure in some patients with diuretic-induced hypokalemia, it
is not possible to predict which patients will respond. More-
over, as an editorial accompanying the report noted, there have
been few attempts to consider the potential risks of potassium
administration [361.
The possible mechanisms of the antihypertensive effect of
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Fig. 4. Mean arterial blood pressure compared with urinary sodium
excretion at the end of each dietary period for 14 normotensive men
receiving (•) or not receiving (0) potassium. Bars represent SEM.
(From Ref. 37.)
potassium supplementation are listed in Table 1. It appears that
potassium supplementation is most effective in normotensives
and in hypertensive patients whose blood pressures are salt
sensitive. For example, Weinberger et al observed the effects of
graded increases in dietary sodium from 10 to 1500 mEq/day
(assessed by changes in urinary sodium excretion) on 14 nor-
motensive men (7 black, 7 white) [371 (Fig. 4). Blood pressure
increased at lower levels of sodium intake and to a greater
extent in blacks than in whites. In additional studies, these
investigators administered potassium at the time of sodium
loading (to offset renal potassium losses caused by sodium
loading) and observed attenuation of increases in blood pres-
sure [371. McQuarrie and colleagues were the first to demon-
strate the potent natriuretic properties of potassium chloride
[381. They studied several young diabetic patients with salt-
sensitive hypertension and observed that the administration of
potassium chloride at the time of sodium chloride loading
prevented sodium chloride-induced increases in blood pressure
in association with marked weight loss. Tabuchi et al deter-
mined the effect of sodium loading with and without potassium
supplementation in 10 patients with essential hypertension who
were ingesting low-salt (50 mEq/day) diets [391. After 5 days of
sodium chloride (300 mEq/day), systolic blood pressure in-
creased from 124 4 mm Hg to 150 5 mm Hg (P < .01), and
the diastolic blood pressure rose from 77 3 mm Hg to 89 4
mm Hg (P < .0 1). At that time, potassium intake was increased
from 60 to 156 mEq/day by the addition of a timed-released
potassium compound. There were reductions in both systolic
(150 5 to 131 5mm Hg) and diastolic (89 4 to 83 3 mm
Hg) pressure.
The protective effect of potassium supplementation is medi-
ated by the attenuation of increases in cardiac output induced
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High K Normal K Low K
Urinary Na (mmollday)
Plasma volume
(% of normotensive controls)
Mean arterial pressure
(mm Hg)
183.1 8.1"
77.8 2.4"
103 3C
158.2 8.9
83.5 2.5
114 3
130.7 7.0
87.7 2.9
111 3
by sodium chloride loading. In one study, dietary sodium intake
was restricted for 18 weeks in 40 young hypertensive subjects
[401. According to a double-blind, randomized, crossover pro-
tocol, patients received in random sequence sodium chloride
(90 mmollday), potassium chloride (72 mmol/day), and placebo
for 6-week periods. The administration of sodium chloride
produced no changes in blood pressure. The combination of
low-sodium/high-potassium diet resulted in small reductions in
mean systolic blood pressure (average, 3.3 mm Hg). Decreases
in blood pressure were associated with 9% decreases in cardiac
output (P < .05).
Potassium supplementation appears to attenuate increases in
total-body sodium induced by sodium chloride loading. For
example, Fujita, Ando, and Noda studied the effect of potas-
sium chloride on sodium balance in 23 hypertensive patients
who had come into balance on a low-sodium diet (25 mmol/
day). The patients were then given sodium chloride (250 mmol/
day) with or without potassium chloride (96 mmol/day) [41, 42].
Whereas mean blood pressure increased by 9% in the patients
given sodium chloride alone, mean blood pressure did not
increase in patients given potassium chloride with the sodium
chloride load. With the high-sodium chloride diet, potassium
chloride-supplemented patients showed lesser increases in
plasma volume and cardiac output than did non-potassium
chloride-supplemented subjects. Moreover, potassium chloride
administration resulted in less cumulative sodium retention. An
estimate of the mean cumulative sodium retention over 6 days
of a high-sodium chloride diet was 209 35 mmol for the
potassium chloride-supplemented group and 311 32 mmol for
the non-potassium chloride-supplemented group. These results
suggest that potassium supplementation prevents increases in
blood pressure in sodium chloride-sensitive patients by increas-
ing urinary sodium excretion and thereby preventing sodium
chloride-induced increases in cardiac output.
Another way to elicit the relationship between changes in
total-body potassium and sodium is to determine the effect of
potassium depletion on sodium excretion. limura et al com-
pared urinary sodium excretion in 20 patients with essential
hypertension on a normal potassium diet (75 mmol/day) or after
a high-potassium (175 mmol/day) or low-potassium (25 mmol/
day) diet [43]. Potassium loading and restriction were per-
formed in a crossover design, with 10 patients receiving the
high-potassium diet first and 10 patients receiving the low-
potassium diet first (Table 2). After potassium loading, urinary
sodium excretion increased and plasma volume decreased in
subjects taking supplemental potassium, whereas urinary so-
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Fig. 5. Daily urinary sodium excretion in individuals on potassium
intakes of 90 (•) or 10 (0) mmol/day. The asterisk (P < .05) and dagger(P < .01) indicate significant differences between the two diets. (From
Ref. 44.)
dium excretion decreased and plasma volume increased in
subjects during potassium restriction.
Using a randomized crossover design, Krishna et al studied
the effects of potassium depletion on sodium balance and blood
pressure in 10 normotensive men [44]. Subjects consumed an
isocaloric diet on a fixed sodium intake of 120 to 200 mmollday.
Potassium intake was maintained at 10 or 90 mmol/day (potas-
sium chloride tablets). Figure 5 demonstrates the effect of these
two diets on urinary sodium excretion. Beginning with the first
day of the study, urinary sodium excretion was higher in
patients consuming 90 mmol of potassium compared with 10
mmol of potassium. Subjects remained in external potassium
balance when potassium intake was 90 mmol/day. When potas-
sium intake was restricted, however, the net positive sodium
balance was 396 63 mmol over the 9-day study period. In
association with increases in total-body sodium during potas-
sium restriction, mean arterial pressure increased from 90.9
2.2 mm Hg to 95.0 2.2 mm Hg (P <
.05).
Taken together, the results of studies in normotensive and
hypertensive individuals strongly suggest that changes in di-
etary potassium alter sodium balance. Potassium restriction
results in sodium retention, whereas potassium supplementa-
tion appears to cause a natriuresis and prevent sodium retention
in response to sodium chloride loads.
Other possible mechanisms could account for the vasodila-
tory effects of potassium (Table 2). For example, changes in
total-body potassium affect circulating levels of vasoconstrictor
hormones. Although increases in total-body potassium consis-
tently decrease renin production in animals [45, 46], few studies
have reported decreases in renin production in humans during
potassium administration [35]. In fact, potassium supplementa-
tion increased plasma renin activity in some studies [39, 41, 43].
The mechanism of the potassium-renin interaction in humans
has been studied by Miller and colleagues in adrenalectomized
patients taking fixed gluco- and mineralocorticoid replacement
therapy 147]. Five subjects were studied under balance condi-
tions on fixed sodium intakes (100 to 150 mEq/day). When
dietary potassium intake was increased to 200 to 300 mEq/day,
Table 2. Effect of potassium intake on urinary sodium excretion,
plasma volume, and mean arterial pressure in patients on various
potassium intakesa
a Adapted from Ref. 43.b P < .001 high potassium versus low potassium.
P < .005 high potassium versus low potassium.
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urinary sodium excretion and plasma renin activity increased
markedly. In 3 studies, net sodium balance was —273 mEq over
3 days. Plasma renin activity increased from 1.2 to 12.5 ng/mL/
hr. Increases in plasma renin activity were prevented when
urinary sodium losses were replaced. These results indicate that
increases in plasma renin activity associated with potassium
administration are the result of potassium-induced natriuresis
rather than a direct effect of potassium.
Potassium administration increases aldosterone production
by the adrenal glomerulosa by stimulating key enzymes in the
aldosterone biosynthetic pathway and by potentiating angioten-
sin IT-induced aldosterone production. Whereas some clinical
studies have found increases in plasma or urinary aldosterone
after potassium supplementation, this observation is not uni-
form [41—44, 48, 49]. The effects of potassium supplementation
on catecholamine metabolism have been inconsistent [39, 41—
43, 48—501. The effect of potassium supplementation on va-
sodilatory hormones has not been carefully evaluated. In one
study, Tabuchi and coworkers reported that potassium supple-
mentation increased plasma prostaglandin E2 concentration
[39]. But other studies have found that changes in total-body
potassium do not alter urinary PGE2 excretion [511. The effects
of potassium administration on norepinephrine and angiotensin
II pressor sensitivity are variable [43, 49—511, and the effect on
baroreceptor sensitivity is small and inconsistent [48, 491.
Thus, the mechanisms of the modest reduction in blood
pressure by potassium administration appear to be mediated by
potassium-induced natriuresis and decreases in volume.
Changes in other determinants of blood pressure are small or
inconsistent.
Animal investigations. Many studies in normotensive and
hypertensive rats indicate that potassium supplementation re-
duces blood pressure. Perhaps the first demonstration of a
protective effect of potassium chloride was reported by Me-
neely and Ball [52], who gave normotensive rats diets with a
high sodium chloride content. These investigators studied the
effect of dietary sodium chloride on survival and assumed that
death was caused by sodium chloride-induced increases in
blood pressure and cardiovascular events. Control rats con-
sumed a diet of either 0.15% sodium chloride or 0.66% potas-
sium chloride. Compared with control rats, the administration
of a 5.6% sodium chloride diet shifted the survival curve to the
left. In contrast, when sodium chloride was administered to
animals consuming a high-potassium chloride diet (2.9%), sur-
vival was greater than in the rats on the control diet. Moreover,
sodium chloride loading in the setting of potassium chloride
loading increased median survival by 7 months, compared with
sodium chloride loading without extra potassium chloride.
In a classic study, DahI and colleagues evaluated the effects
of alterations in the molar ratios of sodium and potassium in the
diet on systolic blood pressure in salt-sensitive hypertensive
rats [53]. The rats were given diets of varying ratios of sodium
to potassium, ranging from 10 to I. All diets were high in
sodium chloride (4.5%), but they differed in potassium chloride
concentration according to the aforementioned ratios. After 12
months of the diets, systolic blood pressure was approximately
170 mm Hg in the rats on the diet with a sodium-to-potassium
ratio of 10, but only 135 to 140 mm Hg in the rats on the diet
with a sodium-to-potassium ratio of I. These studies were of
special importance because they indicated a moderating effect
of potassium chloride on sodium chloride-induced hyperten-
sion. Moreover, they suggested that the molar ratio of sodium
chloride and potassium chloride had more important effects on
blood pressure than the absolute amount of sodium chloride.
Recent studies have shown a moderating effect of potassium
chloride in another model of salt-sensitive hypertension,
DOCA-salt rats. Fujita and Sato administered DOCA and extra
salt to uninephrectomized rats consuming rat chow [54]. When
0.2% potassium chloride was added to the rats' drinking water,
there was a marked decrease in blood pressure. For example,
after 4 weeks of DOCA and sodium chloride, systolic blood
pressure exceeded 180 mm Hg in rats without potassium
chloride supplementation but was only 150 mm Hg in rats
receiving potassium chloride.
Potassium also modulates hypertension in experimental mod-
els generally not considered salt sensitive, such as the sponta-
neously hypertensive rat (SHR) [55] and in rats with renovas-
cular hypertension (RVH) [56]. Suzuki et al determined the
effect of potassium chloride (.5% KC1 in drinking water) on
two-kidney, one-clip renovascular hypertension 1561. When
administration of potassium chloride was begun when the renal
artery was clipped, a protective effect on systolic blood pres-
sure could be identified within 2 weeks. After 4 weeks, the
systolic blood pressure had risen to over 180 mm Hg in rats
without potassium chloride supplementation, compared with
pressures of 140 to 150 mm Hg in potassium chloride-supple-
mented animals. In additional studies, the investigators main-
tained rats on normal diets for 2 weeks after clipping the renal
artery. Potassium then was added to the drinking water of some
of the animals. Whereas systolic blood pressure continued to
increase in rats that had not been potassium supplemented,
systolic blood pressure did not increase further in rats given
potassium supplements. These studies demonstrate that potas-
sium supplementation has the potential to lower blood pressure
even after the development of renovascular hypertension.
However, these results in RVH along with those in the SHR
[55] underscore one of the disappointing aspects of the effect of
potassium supplementation in sodium chloride-insensitive ex-
perimental models of hypertension. In these settings, potassium
chloride lowers the blood pressure but does not return the blood
pressure to normal values. Furthermore, not all studies have
revealed a protective effect of potassium supplementation in
salt-insensitive animal models of hypertension [57].
As in the clinical studies, experimental data are limited on the
protective mechanism of potassium supplementation. It is clear
that potassium administration results in natriuresis. When nor-
motensive rats were fed high-sodium chloride diets (8.4% to
9.8% NaC1), blood pressure increased markedly [581. Increases
in blood pressure were associated with increases in both sodium
space and exchangeable sodium. The addition of potassium
chloride (5.3% to 6.1%) to the high-sodium chloride diets
partially offset increases in blood pressure as well as increases
in sodium space and exchangeable sodium. Fujita and Sato
studied the role of natriuresis in the protective effect of potas-
sium against DOCA-salt hypertension [59]. The administration
of either 0.2% or 1.0% potassium chloride along with DOCA
and salt attenuated increases in systolic blood pressure in a
dose-dependent fashion; at 4 weeks the systolic blood pressure
was 177 3 mm Hg in controls compared with 131 3 mm Hg
(0.2% KC1) and 120 3 mm Hg (1% KC1) respectively.
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Compared with vehicle-treated control rats, exchangeable so-
dium markedly increased in the DOCA-salt rats. These
increases were less marked in rats given either one of the
potassium chloride supplements. Moreover, because a close
correlation existed between systolic blood pressure and ex-
changeable sodium in DOCA-salt rats (in control as well as in
potassium-supplemented animals), it appeared that the antihy-
pertensive effect of potassium supplementation was mediated
by a potassium-induced prevention of expansion of extracellu-
lar fluid volume.
The natriuretic effect of potassium is a direct effect of
potassium on sodium chloride reabsorption by the kidney.
When potassium chloride is infused into the renal artery,
sodium excretion increases; this rise appears to be mediated by
reductions in proximal sodium reabsorption [60, 61]. Young et
al studied the effect of increasing potassium intake (30 to 200
rnEq/day) on sodium balance in normotensive dogs [621. After 6
days, the cumulative negative sodium balance was 44 mEq, and
the 22sodium space decreased by 6.7%. These decreases in
total-body sodium occurred in the setting of increases in plasma
potassium (.47 mEq/liter) and aldosterone (58%). Mean arterial
pressure did not change. To determine the role of aldosterone
on sodium balance, the protocol was repeated in adrenalecto-
mized dogs on fixed replacement doses of aldosterone and
hydrocortisone. When the aldosterone dose was fixed, the
administration of potassium chloride resulted in a greater so-
dium loss (84 mEq over 5 days) and larger decreases in mean
arterial pressure (110 3 to 96 3 mm Hg) than when the
adrenals were intact. These results indicated that changes in
total-body and plasma potassium within physiologic limits have
substantial effects on sodium balance.
Although it appears that the natriuretic effect of pOtassium
supplementation might be important in sodium chloride-sensi-
tive hypertension, it is not known whether potassium induces
natriuresis in other experimental models, or whether decreases
in sodium balance mediate the protective effect of potassium in
non-sodium chloride-sensitive hypertension. The central hemo-
dynamic mechanism of the protective effect of potassium sup-
plementation has been determined in the spontaneously hyper-
tensive rat. Workman and Pallcr found that mean arterial
pressure was reduced from 188 1 mm Hg to 172 4 mm Hg
(P < .025) after 3 weeks of dietary potassium supplementation
in these animals [55]. Decreases in mean arterial pressure were
mediated by reductions in systemic vascular resistance: 0.58
0.06 mm Hg to 0.45 0.02 mm Hg m1' kg (P < 0.05).
Reductions in systemic vascular resistance could be a direct
effect of potassium on vascular smooth muscle cells or might be
mediated by reductions in pressor hormone levels or reductions
in vascular sensitivity to endogenous pressor hormones. Al-
though information about the effect of physiologically attainable
levels of potassium on the contractile state of vascular smooth
muscle is limited, potassium supplementation clearly alters the
levels of, as well as vascular sensitivity to, renin and angioten-
sin II in animals. Circulating levels of renin [45, 56] and
angiotensin II [63] appear to be decreased in animals with a high
potassium intake. Moreover, potassium supplementation ap-
pears to decrease pressor sensitivity to angiotensin II in intact
animals. Potassium supplementation also appears to decrease
pressor sensitivity to norepinephrine and alters norepinephrine
metabolism in DOCA-salt rats [54].
In addition to decreasing the activity of pressor hormones,
high-potassium diets augment endothelium-dependent relax-
ation [64, 651. For example, Raij et al studied the effects of
high-potassium diets on aortic ring reactivity in Dahi salt-
sensitive rats [64]. In precontracted rings from rats on a
high-salt diet, the vasodilatory responses to an endothelium-
dependent vasodilator substance (acetylcholine) were de-
creased compared with the responses of rats on low-salt diets.
Potassium supplementation enhanced endothelium-dependent
vasodilatory responses in rats on high-salt diets. Vasodilatory
responses to non-endothelial-dependent substances (such as
nitroprusside) were not altered by potassium supplementation.
These data suggest that the antihypertensive effects of dietary
potassium supplementation might be mediated by the direct
effects of potassium on endothelial function.
Epidemiologic studies have suggested effects of potassium on
vascular injury that are not mediated by potassium-induced
decreases in blood pressure. Tobian and colleagues studied the
effect of potassium supplementation on renal injury in DahI
salt-sensitive rats [66]. The animals were given high-sodium
chloride diets (4%) without added potassium chloride or with
potassium nitrate or potassium chloride. These studies showed
no beneficial effect of potassium on blood pressure, as all 3
groups developed hypertension. Rats on the high-sodium chlo-
ride diet developed renal arteriole lesions (thickened walls and
narrowed lumens) as well as focal tubular dilation. Both potas-
sium nitrate and potassium chloride reduced vascular and
tubular injury.
In subsequent studies, Tobian's laboratory showed that di-
etary potassium supplementation reduces cerebral hemorrhage
and death rate in stroke-prone spontaneously hyperactive rats.
Potassium supplementation reduced stroke rate, and this reduc-
tion occurred in the absence of decreases in blood pressure [67].
As in Dahl salt-sensitive rats [64], endothelium-dependent
relaxation responses of precontracted aortic rings were dimin-
ished in stroke-prone SHR [651; the administration of potassium
reversed these abnormalities. Furthermore, potassium admin-
istration prevented aortic and mesenteric artery intimal lesions
observed in non-potassium-supplemented stroke-prone SHR.
These data, like those of Raij [641, suggest that potassium
supplementation exerts a direct, protective effect on endothe-
hum.
Potassium depletion: Animals
In contrast to the apparent hypertensive effect of potassium
depletion in normotensive patients, potassium depletion often
reduces blood pressure in normotensive animals [68]. Reduc-
tions in blood pressure are mediated by decreases in systemic
vascular resistance. Potassium depletion also lowers urinary
sodium excretion and produces net positive sodium balance and
increases in cardiac output [68]. The increase incardiac output
can offset the hypotensive effects of a decrease in systemic
vascular resistance. The net effect of potassium depletion on
blood pressure therefore is variable. In the initial study of this
problem, potassium deficiency over 3 weeks in dogs reduced
systemic vascular resistance by 33%. This decrease in vascular
resistance was associated with markedly positive sodium bal-
ance (374 38 mEq) and with increases in body weight (10%),
plasma volume (45%), and inulin space (33%). In addition,
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cardiac output increased by 40% [69]. Because of these offset-
ting effects on vascular resistance and cardiac output, mean
arterial pressure was unchanged.
In association with reductions in systemic vascular resis-
tance, potassium depletion increases plasma renin activity (45,
46) and plasma angiotensin II concentration [631, and causes
pressor resistance to endogenous and exogenous angiotensin II.
Because potassium depletion conveys pressor resistance to
angiotensin II, we questioned whether the hypotensive effect of
potassium depletion might ameliorate renin-dependent hyper-
tension, as in the early phase of two-kidney, one-clip renovas-
cular hypertension [70]. This effect had been postulated by
Fisher and Funckes more than 20 years ago [71]. When rats
were potassium depleted prior to receiving a renal artery clip,
potassium depletion prevented the development of hyperten-
sion. Moreover, when the animals were allowed to become
hypertensive on potassium-replete diets, the substitution of
low-potassium diets ameliorated high blood pressure. Our ini-
tial studies were performed utilizing diets with a very low
potassium content (5 mEq/kg diet). The rats did not grow
normally on these diets, so it was possible that the antihyper-
tensive effect of potassium was mediated by the nonspecific
effects of growth retardation rather than specifically by potas-
sium depletion. We performed additional studies utilizing more
moderate potassium depletion (54 mEq/kg diet). In these stud-
ies, growth initially lagged in the animals on the potassium-
depleted diets, but by 6 weeks, weight gain was comparable in
the potassium-replete and potassium-depleted animals. Serum
potassium fell from 3.8 0.1 mg/liter to 3.6 0.1 mEq/liter;
muscle potassium was reduced by 9% in the potassium-depleted
animals. Moderate potassium depletion prevented the develop-
ment of, and ameliorated established, two-kidney, one-clip
renovascular hypertension. Hypertension in two-kidney, one-
clip renovascular hypertension is hemodynamically caused by
increases in systemic vascular resistance. The hemodynamic
mechanism of the protective effect of potassium depletion was
a reduction of increases in systemic resistance.
Because moderate potassium depletion appeared to have
such a potent vasodilatory effect on renin-dependent hyperten-
sion, we questionedwhether potassium depletion could have a
broader antihypertensive effect [72]. In the spontaneously
hypertensive rat, we found that administration of the moder-
ately potassium-depleted diet prevented hypertension (systolic
blood pressure, 122 3 mm Hg in the potassium-depleted
animals versus 155 5 mm Hg in the potassium-replete
animals, P <
.01). Further, the diet ameliorated established
hypertension (128 3 mm Hg in the potassium-depleted
animals versus 171 5 mm Hg in the potassium-replete
animals, P <
.01). The antihypertensive effect of potassium
depletion was associated with a 5% to 6% reduction in muscle
potassium and was mediated by the marked reductions of
increases in systemic vascular resistance that are characteristic
of this model of hypertension.
The effect of potassium depletion in renoprival hypertension
is shown in Figure 6. In these studies, rats were given the
severely potassium-depleted diet (5 mEq/kg diet) or the normal-
potassium (240 mEq/kg diet) diet for 3 days prior to bilateral
nephrectomy. After recovery from anesthesia, all animals were
given the potassium-deficient diet as well as 5% glucose and
0.5% sodium chloride in drinking water. The figure demon-
P < 0.01 vs Days post nephrectomy
K Deplete
Fig. 6. Systolic blood pressure in rats with renoprival hypertension.
strates that over the ensuing 2 days, systolic blood pressure
increased from 110 5 mm Hg to 146 7 mm Hg (P < .01) in
potassium-replete rats, whereas systolic blood pressure re-
mained stable (102 2 mm Hg to 99 4 mm Hg) in the
potassium-depleted animals. Although we did not perform
hemodynamic measurements, Ledingham and Pelling have
shown that increases in blood pressure in rats with renoprival
hypertension are mediated by increases in plasma volume and
cardiac output [73]. Because potassium-depleted and potassi-
um-replete animals consumed the same quantity of food and
water after nephrectomy, we believe that decreases in systemic
vascular resistance induced by potassium depletion offset in-
creases in cardiac output, thereby ameliorating hypertension.
Why have studies of the effect of potassium depletion on
blood pressure yielded such discrepant results? Might the
differences be the consequence of physiologic adaptations to
potassium depletion rather than to potassium depletion per se?
Potassium depletion results in marked increases in total-body
sodium and in cardiac index. Both of these responses to
potassium depletion could offset primary reductions in systemic
vascular resistance observed in potassium-depleted normoten-
sive and hypertensive animals. To determine the role of phys-
iologic adaptations to potassium depletion, we recently have
performed two series of studies, reported here for the first time.
In the first, we attempted to prevent potassium-depletion-
induced increases in sodium balance. Sprague-Dawley nor-
motensive rats were maintained on one of three diets: (1) low
potassium (5 mEq/kg diet), normal sodium (230 mEq/kg diet);
(2) low sodium (10 mEq/kg diet), normal potassium (210 mEq/kg
diet); or (3) low potassium, low sodium. Figure 7 shows the
results of this study. The three groups were well matched with
reference to blood pressure as they began the dietary protocols.
Sodium balance was positive before the diets were started
because the animals were growing. The institution of the
potassium-depleted diet produced small decrements in blood
pressure despite increases in net positive sodium balance.
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Fig. 7. Systolic blood pressure in normotensive rats on low-potassium,
low-sodium, or low-potassium, low-sodium diets.
Table 3. EffeCt of beta-blockade on central hemodynamics d
potassium depletion
uring
MAPS CI SVR
(mm Hg) (mi/mm . kg) (mm Hg/mi. min' . kg)
Low K 110 3 412 18 0.27 .02
(N =8)
Low K plus
beta-blocker 96 2b 322 0.30 .03
(N = 6)
Control 121 3C 318 I6' 0.38
(N = 6)
When potassium-depleted animals were prevented from going
into positive balance (via a low-potassium, low-sodium diet),
we found further decrements in blood pressure. Sodium
depletion alone was neutral with respect to blood pressure
despite small decreases in sodium balance.
In the second study, we performed hemodynamic evaluations
on Sprague-Dawley rats that had undergone 7 days of dietary
potassium depletion (5 mEq/kg diet). Before the hemodynamic
studies, the rats were treated with the beta-blocker propranolol
to offset increases in cardiac output observed during potassium
depletion. Cardiac output was determined by the radioactive
microsphere technique, and systemic vascular resistance was
calculated from mean arterial pressure and cardiac output data.
Potassium depletion reduced systemic vascular resistance by
25% (Table 3). Decreases in systemic vascular resistance were
partially offset by increases in cardiac output. In the setting of
beta blockade, decreases in systemic vascular resistance were
not associated with increases in cardiac output, and mean
arterial pressure fell substantially.
These results suggest that potassium depletion reduces sys-
temic vascular resistance but that an adaptive increase in
cardiac output during potassium depletion offsets this primary
effect. These phenomena are depicted in Figure 8. Because
potassium depletion has disparate effects on the two determi-
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Fig. 8. Integrated scheme of the effects of potassium depletion on
central hemodynamics. SVR = systemic vascular resistance; UNaV =
urinary sodium excretion.
nants of blood pressure, the net effect of potassium depletion on
blood pressure might be expected to be variable. Decreases in
sodium excretion might offset any antihypertensive effect of
potassium depletion on systemic vascular resistance. Although
data in animals support this hypothesis, only limited clinical
information is available. The study by Krishna et al seems to
support this hypothesis [44]. When subjects were potassium
depleted, small increases in blood pressure were observed.
However, in the setting of sodium chloride loading, potassium-
depleted patients were unable to excrete the sodium chloride,
and brisk increases in blood pressure were noted. It will be
important to determine central hemodynamics in potassium-
depleted human subjects and to find out whether the hyperten-
sive effect of potassium depletion in humans can be prevented
by dietary sodium chloride restriction.
Cellular effects of potassium
Because changes in total-body potassium alter a number of
systems that are important in the control of blood pressure, the
direct effects of potassium on vascular tissue have been studied
in isolated systems, including isolated vascular beds, vascular
strips, and vascular smooth muscle cells (VSMC) in culture.
Although not extensively studied in isolated vessels and
arterial strips, small increases in potassium (8—10 mM) hyper-
polarize (vasodilate), and decreases in potassium (1—2 mM)
depolarize (vasoconstrict), vascular tissue [74—83]. These ef-
fects would not be anticipated on the basis of the potassium
diffusion potential across vascular smooth muscle plasma mem-
branes [84, 851. The diffusion potential across vascular tissue is
large and negative with regard to the cell interior. It is primarily
potassium dependent because intracellular potassium concen-
tration and conductance are very high in this tissue. Thus
increases in extracellular potassium would be expected to blunt
the potassium diffusion potential and result in depolarization of
vascular tissue.
The transmembrane potential across vascular smooth muscle
is determined by the potential generated by the activity of the
enzyme sodium-potassium-ATPase as well as the potassium
diffusion potential, however. The electrical contribution of the
sodium pump is negative with reference to the cell interior,
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b p < .01 versus low potassium.
C P < .05 versus low potassium.
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because this pump moves 3 sodium ions from inside to outside
and 2 potassium ions in the opposite direction. Sugden et al
showed that even though small increases in potassium blunt the
potassium diffusion potential, increases in dietary potassium
stimulate the activity of vascular sodium-potassium-ATPase
[86]. The net effect of small increases in potassium, therefore, is
an increase in the transmembrane potential, thereby resulting in
hyperpolarization and vasorelaxation. When potassium ex-
ceeds 10 mM, the dominant effect is a decrease in the potassium
diffusion potential; depolarization and vasoconstriction ensue.
Decreases in extracellular potassium increase the potassium
diffusion potential but decrease sodium-potassium-ATPase.
The effects on the sodium pump appear to predominate, and the
net effect of decreases in extracellular potassium is a decrease
in the transmembrane potential; depolarization and vasocon-
striction result. I should note that the effects of potassium on
the contractile state of vascular tissue for the most part have
been determined for acute changes in extracellular potassium.
The effects of changes in intracellular potassium on the trans-
membrane potential, as in clinical conditions, have not been
determined and could differ from the results of the studies of
acute potassium alterations.
Although there are no reports on the effects of increases of
potassium on vascular smooth muscle cells in culture, cellular
potassium depletion does appear to alter VSMC function. In
vivo, potassium depletion decreases pressor sensitivity to angi-
otensin II but not to other pressor hormones such as norepi-
nephrine [87]. The pressor effect of angiotensin II is initiated by
ligand binding to cell-surface receptors on vascular smooth
muscle. Potassium depletion stimulates angiotensin II binding.
For example, we found that potassium depletion was associated
with increases in angiotensin II binding to mesenteric artery
membranes prepared from normotensive and hypertensive rats
[87—89]. Increases in binding were caused by increases in the
apparent number of angiotensin II receptors rather than by
changes in the affinity of those receptors.
Because potassium depletion decreased angiotensin II pres-
sor sensitivity in the setting of increased angiotensin II binding
to vascular tissue, it appeared that decreases in angiotensin II
pressor sensitivity in potassium depletion resulted from defects
in cell function at post-angiotensin Il-binding sites. To investi-
gate angiotensin Il-induced post-receptor events and to deter-
mine the specific effects of angiotensin II and potassium deple-
tion on VSMC function, we studied vascular smooth muscle
cells in culture. In this tissue, angiotensin II binds to cell
surface receptors. After binding, angiotensin II receptors are
rapidly internalized through an endosomal compartment within
cells. The ligand is dissociated from the receptor, and angioten-
sin II receptors are returned to the cell surface [90]. This is a
rapid process, with one cycle requiring less than 5 minutes for
completion at 37°C.
Angiotensin II binding to angiotensin II receptors rapidly
activates phospholipase C (PLC). The PLC-mediated hydroly-
sis of phosphatidyl-inositol 4,5 bisphosphate (PIP2) yields 1,4,5-
inositol trisphosphate (1P3) and diacylglycerol. Whereas 1P3
formation is transient (peaking at 15 seconds and returning to
baseline by 2 minutes), diacylglycerol formation is biphasic.
Diacylglycerol formation peaks at 15 seconds and 5 minutes and
is sustained for up to 20 minutes [91]. In vascular smooth
muscle cells, it appears that the substrate for PLC-mediated
diacylglycerol formation is PIP2 and phosphatidyl-inositol
4-phosphate (PIP) initially, and phosphatidyl inositol (P1) sub-
sequently [90]. Angiotensin Il-generated IP3 causes a release of
calcium from non-mitochondrial sites [92]. Diacylglycerol acti-
vates protein kinase C, which, on activation, translocates from
the cytosol to the cell membrane and phosphorylates a number
of cellular proteins [93—95]. The net consequence of 1P3 and
diacylglycerol formation is sustained vascular contraction.
Whereas the coupling of surface receptors to cellular action
indicates the presence of spare receptors for many ligand-
receptor systems, the relationship between the number of
angiotensin II receptors and angiotensin 11-induced PLC-medi-
ated phosphoinositide hydrolysis suggests that there are no
spare angiotensin II receptors [96]. Reductions in the number of
angiotensin II surface receptors by maneuvers that did not
activate PLC reduced angiotensin 11-induced 1P3 formation, a
decrease comparable in magnitude to that in receptor number
(Fig. 9).
The recycling pathway appears to have several functions in
vascular smooth muscle cells. Maneuvers that impair angioten-
sin II receptor internalization impair late diacylglycerol forma-
tion [97] as well as the ability of vascular smooth muscle cells to
modulate the number of angiotensin II cell-surface receptors
[90]. Under normal circumstances, exposure of VSMC to
angiotensin II results in the loss of receptors from the cell
surface (downregulation). These receptors are trapped in endo-
somes and, after removing angiotensin II, the receptors rapidly
return to the cell surface. Maneuvers that interfere with recep-
tor internalization prevent angiotensin Il-induced downregula-
tion of surface receptors. Decreasing the temperature from 25°C
to 4°C or exposure to phenylarsine oxide (an arsenical com-
pound that prevents receptor movement) prevents downregu-
lation. Moreover, agents that impair endosomal function accen-
tuate angiotensin Il-induced downregulation. Chloroquine and
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ammonium chloride dissipate the endosomal p11 gradient,
thereby preventing both the dissociation of angiotensin II from
its receptor and the subsequent return of receptors to the cell
surface. Thus it appears that the recycling pathway not only
modulates PLC function but also controls the ability of cells to
modulate the number of cell-surface receptors.
Potassium depletion alters the expression and function of
angiotensin II receptors at several different sites. There are
increases in the number of angiotensin II receptors on the
surface of potassium-depleted cells [981. Potassium depletion
interferes with receptor cycling to prevent angiotensin II-
induced downregulation of surface receptors. In this regard,
both the ability to internalize and externalize receptors are
impaired. Whereas a decrease in recovery would be expected to
increase angiotensin Il-induced downregulation, decreases in
internalization appear to be relatively more important; thus
angiotensin Il-induced downregulation is impaired. Finally, as
Delafontaine et al showed, potassium depletion impairs sus-
tained diacylglycerol formation [991. Sustained diacyiglycerol
formation requires receptor internalization, so reductions in
diacylglycerol are most likely the consequence of potassium-
depletion-induced reductions in receptor processing.
The mechanism by which decreases in cellular potassium
alter receptor cycling in vascular smooth muscle cells is not
known. But work in other systems suggests that potassium
depletion inhibits the formation and function of "coated pits"
[100]. Because many receptors are internalized by a coated pit
mechanism, and because potassium depletion alters coated pit
function in other cell types [100—102], potassium depletion
probably impairs angiotensin II receptor internalization by
inhibiting coated pit formation or function in vascular smooth
muscle cells. Alternatively, potassium depletion might affect
cell function via decreases in cell energy availability or alter-
ations in the lipid composition of membranes so that mem-
branes become less fluid.
Conclusion
Epidemiologic studies suggest an inverse relationship be-
tween blood pressure or stroke and potassium intake. Interven-
tional data from humans and animals suggest that potassium has
a modest antihypertensive effect. The antihypertensive effects
of potassium appear to be primarily mediated by the natriuretic
properties of potassium.
Modest increases in dietary potassium (40—60 mmol/day) may
have a beneficial effect on the level of blood pressure and on the
incidence of stroke. As with other dietary modifications, the
beneficial effect of potassium is not always manifest in every
subject. Moreover, potassium supplementation should be
avoided in a number of situations. Potassium supplementation
should be withheld in individuals with decreased renal function,
in the elderly, and in individuals taking potassium-sparing
diuretics, angiotensin converting enzyme inhibitors, or nonste-
roidal antiinflammatory drugs.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Of the
various hypermineralocorticoid, hypokalemic states, some dis-
play hypertension and others do not, for example, primary
aldosteronism versus Bartter's syndrome. On the basis of your
current understanding of the role of potassium in blood pressure
regulation, what role might hypokalemia be playing in the
contrasting blood pressure patterns of these states?
DR. LINAS: This excellent question raises the issue of why
patients with primary aldosteronism are hypertensive, whereas
patients with Bartter's syndrome are normotensive despite
comparable serum potassium and total-body potassium levels.
It is important to recall that blood pressure is the integrated
response to a number of factors, not just total-body potassium.
For example, in primary aldosteronism, there are increases in
mineralocorticoids, decreases in total-body magnesium, and
increases in total-body sodium. All these factors could contrib-
ute to high blood pressure. In contrast, despite increases in
angiotensin II and aldosterone, total-body sodium is not in-
creased in Bartter's syndrome, and there appear to be increases
in vasodilatory prostaglandins such as prostacyclin. Thus, in
the setting of primary aldosteronism or Bartter's syndrome,
potassium depletion is only one of several determinants of
blood pressure, and the primary effect of potassium depletion
could be offset by these other factors. This is best shown in
Table 2, where the hypotensive effect of potassium depletion
was offset by either increases in total-body sodium or cardiac
index.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center): I give
less credence than you do to the results of the study that related
potassium intake to the frequency of strokes. As I recall, the
investigators searched a massive data base for various correla-
tions and found one correlation between potassium intake and
stroke. Yet a causal link between that particular dietary history
and stroke was lacking. Hypertension seemed not to be an
intermediary factor. It worries me to use this kind of study to
prove anything.
DR. LINAs: I agree with your assessment of the study relating
potassium intake to stroke. It is important to recognize that this
was, in fact, an epidemiologic study rather than an attempt at
intervention. As with all epidemiologic studies, it is not possible
to determine cause-and-effect relationships or to generalize
across broad segments of the population, especially when the
correlations are small and the cohort evaluated is homoge-
neous. However, an interesting aspect of this study was that
increases in potassium intake were associated with reductions
in stroke in the absence of potassium-induced reductions in
blood pressure. The data are tantalizing.
DR. KASSIRER: I don't find these results as convincing as you
do. Alvin Feinstein, in a superb analysis, has pointed out the
hazard of interpreting data of this sort [103). I might be willing
to extract from such data a hypothesis, but little more.
DR. LINAS: I agree with you 100%.
DR. MADIAS: Along the same line, I find it bothersome that
several animal studies have failed to demonstrate decreases in
blood pressure following potassium administration. In fact, as
you pointed out, in the studies by Tobian [66, 67], the protective
effect of potassium on stroke was dissociated from an effect on
blood pressure.
Da. LINAS: Dr. Louis Tobian and his group have shown that
potassium supplementation protects against endothelial dys-
function in several strains of rats. The protection occurs with
minimal or no changes in blood pressure. Although this obser-
vation was originally perplexing, both Tobian [65] and Raij [64]
Nephrology Forum: Potassium and hypertension 783
have shown that potassium supplementation appears to protect
the endothelium from hypertensive injury, both morphologi-
cally and functionally. Thus, potassium supplementation re-
versed decreases in endothelium-dependent relaxation in
hypertensive rats and prevented hypertensive endothelial le-
sions in the stroke-prone spontaneously hypertensive rat.
DR. KASSIRER: I believe it is appropriate to challenge the
notion that a fall in blood pressure of a few millimeters produces
a dramatic change in patient outcome [351. Although there is a
statistically significant difference between the diastolic pressure
of potassium-treated versus nontreated individuals in the Siani
study [33], the absolute difference in diastolic pressure between
the treated group and the untreated group is extremely small.
The same goes for all these other studies in humans. The best of
the results in Kaplan's patients was a reduction of only a few
millimeters of mercury. The extrapolation from these studies is
that small changes in blood pressure can make a tremendous
difference in morbidity or mortality. What is the evidence for
such a change in outcome? Do we have clear evidence that a
change in blood pressure of three or four millimeters of mercury
with the administration of a potassium supplement has a long-
term beneficial effect?
DR. LINAs: The evidence that small decreases in blood
pressure are associated with reductions in stroke or myocardial
infarction comes from large epidemiologic surveys or life insur-
ance tables. As you have noted correctly, it is not possible to
generalize from small interventional studies of 10 to 30 patients
to large populations, especially when changes in blood pressure
in the interventional studies appear to be modest. Moreover, all
the interventional studies utilizing potassium to treat hyperten-
sion have followed blood pressure rather than stroke, or myo-
cardial infarction, for example, as an end point. Thus we do not
have clear evidence that the small changes in blood pressure
associated with potassium therapy will ultimately translate into
decreases in morbidity and mortality.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): Has there been any analysis of the
anion that is either administered with potassium or removed
from the diet in association with potassium depletion?
DR. LINAS: As you are aware, Kurtz et al have shown that
sodium-sensitive hypertension appears to depend on the anion
administered with sodium [1041. Although administration of
sodium chloride resulted in increases in blood pressure, admin-
istration of sodium citrate did not. I am not aware of studies
comparing the hypotensive effect of potassium chloride with
other anions accompanying potassium.
DR. MADIAS: In trying to relate the animal data with those in
humans, I would have predicted that hypertensive subjects
treated with diuretics who develop hypokalemia should be
protected from sustaining positive sodium balance; thus the
accompanying hypokalemia should contribute to, rather than
antagonize, the decrease in blood pressure. Why then does
administration of potassium in such a setting exert a hypoten-
sive effect, at least in some of these patients?
DR. LINAS: There are a number of possible explanations for
the observation that potassium appears to exert hypotensive
effects in patients receiving diuretics. (1) Potassium might exert
its hypotensive effect through non-volume-mediated mecha-
nisms such as reductions in activity of pressor hormones. (2) It
is difficult to show decreases in total-body sodium in hyperten-
sive patients chronically treated with diuretics. Under these
circumstances, potassium administration would be the primary
mechanism for reducing total-body sodium. (3) Even in the
setting of diuretic-induced loss of total-body sodium, the neph-
ron site of action of potassium appears to differ from that of
thiazide diuretics. Whereas thiazides decrease distal-nephron
sodium reabsorption, potassium primarily decreases proximal-
tubular sodium reabsorption. In this setting, the administration
of potassium would be additive to that of hydrochiorothiazide in
reducing total-body sodium.
DR. MADIAS: Were the animal studies on the effects of
potassium depletion on blood pressure regulation controlled for
accompanying hypomagnesemia?
DR. LINA5: Although we did not measure total-body magne-
sium in our potassium-depleted animals, it is unlikely that these
rats were magnesium depleted because the diets were high in
magnesium.
DR. PAUL KURTIN (Chief, Division of Pediatric Nephrology,
New England Medical Center): If you add potassium-rich food
to the diet, you obviously adjust other nutrients as well. For
example, milk is rich in potassium but it is also high in calcium,
and calcium might affect blood pressure. If the diet is kept
isocaloric and isonitrogenous, some nutrients are taken away if
others such as potassium are added. It might be difficult,
therefore, to isolate the effect of potassium alone.
DR. LINAS: You bring up an excellent point. The epidemio-
logic studies clearly indicate correlations among various dietary
constituents. For example, potassium intake correlates highly
with calcium and protein intake. Thus, it is often difficult to use
epidemiologic studies to assign an independent association
between potassium and blood pressure. Interventional studies,
although easier to interpret, suffer from not being dietary
intervention trials. Rather, in these studies, potassium is given
as a supplement; nothing is removed from the diet. Under these
circumstances, changes in blood pressure can be directly attrib-
uted to potassium (and, possibly, to the anion accompanying
potassium).
DR. KURTIN: What about the relationship between potassium
and insulin? Might not there be insulin resistance in hypokale-
mia, which could have an effect on blood pressure by affecting
sodium-lithium countertransport?
DR. LINAs: This issue is somewhat controversial, but I think
it is fair to state that insulin per se might raise blood pressure.
This hypertensive response could occur via a number of mech-
anisms. These include renal sodium retention and activation of
the sympathetic nervous system. Evidence that insulin raises
blood pressure in long-term studies is lacking, however. In
addition to direct effects on blood pressure, substantial evi-
dence suggests that insulin per se is a risk factor for coronary
artery disease.
Potassium depletion is associated with glucose intolerance.
But the glucose intolerance of potassium is associated with
decreases in insulin secretion, not decreases in insulin sensitiv-
ity. Because insulin secretion is decreased in potassium deple-
tion, one would not anticipate that potassium depletion in-
creases blood pressure by an insulin-mediated mechanism.
DR. DEMETRIOS VLAHAKOS (Nephrology Fellow, New En-
gland Medical Center): Hypertensive patients, free of cardiac
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edema and eating normal-salt diets, develop only mild hy-
pokalemia (serum potassium, 3.3 to 3.8 mEq/liter) and a potas-
sium deficit no more than 5% of total-body potassium (approx-
imately 200 mEq), even after prolonged intake of diuretics
[1051. This degree of diuretic-induced hypokalemia is not ar-
rhythmogenic in patients with otherwise uncomplicated hyper-
tension [1061. With that in mind, would you suggest that we
replete these patients, namely, otherwise uncomplicated hyper-
tensives on diuretics, with potassium to facilitate their blood
pressure control?
DR. LINAS: I do not want to leave you with the impression
that we believe that potassium depletion is an acceptable
treatment of hypertension. Potassium depletion lowers blood
pressure in animals and has proved useful in our understanding
of vascular smooth muscle function. However, we have no data
that mild potassium depletion reduces blood pressure in hu-
mans. In fact, recent data suggest the opposite [341. Although I
believe that potassium should be considered for the initial
treatment of hypertension, a recent study concluded that sup-
plemental potassium chloride does not reduce the need for
antihypertensive medication in hypertensive men on sodium-
restricted diets 11071. Given the current controversy, my ap-
proach is as follows: in patients receiving diuretics who develop
mild potassium depletion, I decide whether to provide potas-
sium supplementation based on the blood pressure response to
the diuretic. If blood pressure is well controlled, I do not give
potassium. In contrast, when blood pressure is not well con-
trolled, I begin potassium repletion therapy prior to the addition
of a second antihypertensive agent.
Potassium repletion therapy can be undertaken in a number
of ways. Initially, I encourage patients to increase the potas-
sium content of their diet and reduce sodium intake. If this fails
to replete total-body potassium, then potassium repletion ther-
apy can be accomplished with potassium supplements or with
potassium-sparing diuretic agents. Some evidence indicates
that potassium supplementation might not be as effective as
potassium-sparing diuretics. Thus I choose potassium-sparing
diuretics containing amiloride or spironolactone.
DR. KASSIRER: If a patient has persistent hypertension and a
serum potassium of 3.1 mEq/liter, what do you do? I would use
effective antihypertensive drugs.
DR. LINAS: My response to that is, why use a drug when you
can treat the patient nonpharmacologically?
DR. KASSIRER: You are assuming that administering potas-
sium is not tantamount to using a drug.
DR. LINAS: I would agree that potassium is pharmacologic
therapy. However, I am skeptical that one can successfully
modify dietary potassium intake sufficiently to correct deficits
in total-body potassium in many individuals.
DR. KASSIRER: You are assuming that changing a patient's
diet is first, effective, and second, that it only produces a
benefit. I am not sure about that.
DR. LINAs: I agree with you. Another important issue is that
changing diets to include food substances containing more
potassium is potentially expensive.
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